This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Medtronic (MDT) Stock Moves -1.05%: What You Should Know
by Zacks Equity Research
Medtronic (MDT) concluded the recent trading session at $89.29, signifying a -1.05% move from its prior day's close.
Medtronic (MDT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Medtronic (MDT) closed the most recent trading day at $91.97, moving 1.04% from the previous trading session.
Should Franklin U.S. Low Volatility High Dividend Index ETF (LVHD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for LVHD
Medtronic (MDT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Medtronic (MDT) closed the most recent trading day at $91.65, moving +2.17% from the previous trading session.
ISRG Stock Before Q2 Earnings Release: To Buy or Not to Buy?
by Zacks Equity Research
Intuitive Surgical's second-quarter results are likely to reflect solid performance in the company's Instruments & Accessories segment. Improving margins buoy optimism.
Hospital Capex Headwind: Temporary Setback or Lasting Risk for ISRG?
by Indrajit Bandyopadhyay
Intuitive Surgical's global da Vinci growth faces resistance as hospital CapEx tightens abroad, testing leasing and utilization strategies.
Smart Money Going in Senior Health: Key Stocks in Elderly Care
by Urmimala Biswas
RHHBY, NVO, EW and SYK are ramping up senior care innovation as aging populations reshape global healthcare demand.
Hologic's GYN Surgical Dominance: What's Powering the Road Ahead?
by Moumi Mondal
HOLX's GYN Surgical arm gains momentum with Fluent Pro, global expansion and strategic acquisitions fueling growth.
Medtronic (MDT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Medtronic (MDT) closed the most recent trading day at $88.58, moving +1.04% from the previous trading session.
Will J&J's Q2 Results Reflect End of MedTech Issues & Higher Sales?
by Kinjel Shah
JNJ's MedTech unit eyes second-half growth despite China headwinds, U.S. competition and tariff pressure.
ISRG da Vinci 5 Gets European Nod: Will it Boost the Stock's Prospect?
by Indrajit Bandyopadhyay
ISRG's da Vinci 5 wins CE mark, unlocking Europe's surgical robotics market as U.S. adoption shows strong early traction.
Can ISRG Maintain Robotics Edge Amid Rising Rivalry & Budget Strain?
by Indrajit Bandyopadhyay
ISRG posted strong Q1 growth, but rising rivals and tighter hospital budgets test its robotics dominance and pricing power.
Medtronic (MDT) Beats Stock Market Upswing: What Investors Need to Know
by Zacks Equity Research
Medtronic (MDT) closed the most recent trading day at $87.17, moving +1.34% from the previous trading session.
Why Is Agilent (A) Up 5.4% Since Last Earnings Report?
by Zacks Equity Research
Agilent (A) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
J&J's MedTech Segment Slowing Down: Will its Sales Recover in 2025?
by Kinjel Shah
JNJ's MedTech sales face pressure from China and competition but new products may lead to a stronger second half of 2025.
BSX vs. MDT: Which MedSurg Stock Is the Better Investment Now?
by Sridatri Sarkar
As MedSurg demand rises, Boston Scientific and Medtronic compete for dominance. Which stock shows stronger growth momentum now?
Is ISRG's Procedure Growth Enough to Offset Margin Pressures in 2025?
by Indrajit Bandyopadhyay
Intuitive Surgical raises 2025 procedure outlook after strong Q1 growth, but rising costs and tariff pressure weigh on margins.
Why Is Medtronic (MDT) Up 6% Since Last Earnings Report?
by Zacks Equity Research
Medtronic (MDT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
DXCM's Access Gains and Operational Strength Offset Margin Pressures
by Zacks Equity Research
DXCM rides on record patient growth and T2D access gains, but margin pressure and FDA scrutiny cloud the outlook.
BSX's Neuromodulation Arm Sees Growth: Q1 Highlights
by Sridatri Sarkar
Boston Scientific's Neuromodulation unit witnesses 6.8% growth in the first quarter, fueled by strong gains in pain and brain therapy lines.
ISRG Margin Outlook Dips on Tariffs, Demand Signals Stay Strong
by Harshit Gupta
Intuitive Surgical trims margin outlook on tariff headwinds, but strong procedure growth and financial resilience bolster its long-term case.
Can Hologic Lean on Its Strengths in a Tough Macroeconomic Climate?
by Moumi Mondal
HOLX grapples with global headwinds, but growth in Diagnostics and Breast Health service lifts confidence.
Cardiovascular Tailwind Boosts BSX: Here's How to Play the Stock
by Sridatri Sarkar
Boston Scientific rides strong cardiovascular momentum, with booming EP and WATCHMAN sales despite macro headwinds. What is the investment outlook?
Intuitive Surgical Stock Gains 12.7% QTD: Is it Still a Buy Now?
by Indrajit Bandyopadhyay
ISRG's shares seem to recover after declining more than 30% from its all-time high. Is it the right time to invest?
Emerging Markets Power Boston Scientific: Will the Growth Trend Continue?
by Sridatri Sarkar
BSX posts solid Q1 sales growth in emerging markets, reinforcing their role in the company's long-term global strategy.